Immunomodulation by mesenchymal stem cells: Interplay between mesenchymal stem cells and regulatory lymphocytes

doi:10.4252/wjsc.v8.i9.268

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (13313)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series.

Item

Count

PDF

704

WORD

360

HTML

7378

Figures (1-2)

199

Sum=8641

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

534

Download

1234

Sum=1768

Publishing Process of This Article

Item

Count

Browse

1037

Download

1867

Sum=2904

Sep 26, 2016 (publication date) through Apr 30, 2024

Times Cited of This Article

Times Cited (66)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Frontier

World J Stem Cells. Sep 26, 2016; 8(9): 268-278
Published online Sep 26, 2016. doi: 10.4252/wjsc.v8.i9.268

Immunomodulation by mesenchymal stem cells: Interplay between mesenchymal stem cells and regulatory lymphocytes

Oscar Ka-Fai Ma, Koon Ho Chan

Oscar Ka-Fai Ma, Koon Ho Chan, Department of Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong, China

Author contributions: Ma OKF and Chan KH have been involved equally and have read and approved the final manuscript.

Supported by Matching Fund from Stanley Ho Alumni Challenge for Translational Research in Neuroinflammation, No. 20830036.

Conflict-of-interest statement: The author, Oscar Ka-Fai Ma, certify that they have no affiliations with or involvement in any organization or entity with any financial interest. Another author, Dr. Koon Ho Chan, has received research-funding support from Merck Pharmaceutical Ltd, Novartis Pharmaceutical Ltd, Bayer HealthCare Ltd, and has received honorarium for invited lectures from Biogen Idec and UCH Pharma Ltd.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Dr. Koon Ho Chan, Department of Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, 4/F Professorial Block, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China. koonho@hkucc.hku.hk

Telephone: +852-22553315 Fax: +852-29741171

Received: April 28, 2016
Peer-review started: April 29, 2016
First decision: June 16, 2016
Revised: July 15, 2016
Accepted: July 29, 2016
Article in press: July 31, 2016
Published online: September 26, 2016

Core Tip

Core tip: In this review, we summarized the mechanisms involved in regulatory T (T_reg) and B (B_reg) cell induction by mesenchymal stem cells (MSCs). In an inflammatory environment, MSCs secrete various anti-inflammatory cytokines, actively interact with immune cells and modulate them to acquire regulatory properties, thus, generate a tolerogenic environment. Particularly, by inducing T_reg and B_reg cells, the immunomodulation of MSCs is amplified. Therefore, genetic engineered MSCs to enhance their ability to induce T_reg and B_reg cells may increase their therapeutic efficacy.